Impact BioMedical Inc. Introduces Leadership Team to Drive Innovation and Growth
23 Septembre 2024 - 2:00PM
Impact BioMedical Inc. (NYSE American: IBO), a pioneering
biotechnology company dedicated to discovering, developing, and
patenting unique healthcare solutions, is pleased to introduce its
executive leadership team, poised to lead the company through its
next phase of innovation and growth.
“We are excited to introduce our exceptional leadership team,
which brings together a wealth of experience and a shared vision
for driving innovation and growth at Impact BioMedical,” said Jason
Grady, Impact Biomedical’s Director, and Interim CEO of DSS, Inc.
“With their expertise and commitment, we are confident in our
ability to advance our mission and deliver impactful healthcare
solutions.”
Frank D. Heuszel, Chief Executive Officer
(CEO)
Frank D. Heuszel brings experience in executive leadership,
finance, and strategic planning to Impact BioMedical. Prior to
joining DSS, Inc. as CEO in 2019, he had a successful career in
commercial banking, serving in senior executive roles with major US
and international banking organizations. His visionary leadership
and commitment to excellence position Impact BioMedical for
continued success in the healthcare industry. Mr. Heuszel holds an
undergraduate degree in Business Administration from The University
of Texas at Austin and a J.D. degree from The South Texas College
of Law, Houston.
Mark Suseck, Chief Operating Officer (COO)
Mark Suseck, an accomplished leader with experience in public
and private healthcare companies, serves as the Chief Operating
Officer. Mr. Suseck has been with Impact BioMedical since August
2023 and previously served as the chief operating officer of DSS
BioHealth Holdings Inc., where he led company strategy, operations,
licensing, acquisitions, and commercialization. He also served as
the CEO of Vivacitas Oncology Inc., leading strategy, clinical
development, operations, and financing. Mr. Suseck received his
undergraduate degree in economics from Rutgers University, with
minors in education and philosophy. He completed the Executive
Management Program in residence at the University of Michigan
Business School.
Todd Macko, Chief Financial Officer (CFO)
Todd Macko, a seasoned financial executive, joins Impact
BioMedical as the Chief Financial Officer, while continuing to
serve as CFO of DSS Inc. Mr. Macko has been with DSS since January
2021, initially serving as Secretary and Treasurer, and became CFO
in May 2023. Mr. Macko brings over 25 years of public and corporate
fiscal management experience, with strengths in financial planning
and analysis, business process re-engineering, and mergers and
acquisitions. Mr. Macko obtained his Bachelor of Science degree in
Accounting from Rochester Institute of Technology.
“We are thrilled to have such a talented and experienced
leadership team guiding Impact BioMedical,” said Frank D. Heuszel,
CEO of Impact BioMedical. “Each member of our executive team brings
unique skills and a shared commitment to our mission of developing
innovative healthcare solutions. Together, we are well-positioned
to drive the company’s growth and deliver impactful results for our
stakeholders.”
About Impact BioMedical, Inc.:Impact BioMedical
Inc. (“IBO”) discovers, confirms, and patents unique science and
technologies resulting in new offerings in human healthcare and
wellness. IBIO works closely with licensing, co-development, joint
ventures, and other relationships to bring these offerings to
market. For more information, visit Impact BioMedical, Inc.
About DSS, Inc.:DSS is a multinational company
operating businesses within four diversified market sectors. For
more information on DSS, visit DSS World.
Safe Harbor Disclosure:This press release
contains forward-looking statements within the meaning of Section
27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. These statements are subject to risks and
uncertainties that may cause actual results or events to differ
materially from those projected. Readers are cautioned not to place
undue reliance on forward-looking statements, which speak only as
of the date.
Media Contact:Emily Martin
Email: emartin@impactbiomedinc.com
Investor Relations:info@impactbiomedinc.com
Impact Biomedical (AMEX:IBO)
Graphique Historique de l'Action
De Nov 2024 à Déc 2024
Impact Biomedical (AMEX:IBO)
Graphique Historique de l'Action
De Déc 2023 à Déc 2024